Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note published on Saturday. The firm issued a hold rating on the medical research company’s stock.

A number of other research firms have also recently issued reports on CTSO. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Thursday, April 3rd. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research note on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cytosorbents currently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.09 on Friday. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The business’s fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.01. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market cap of $68.13 million, a PE ratio of -3.03 and a beta of 1.17.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The company had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $10.09 million. Analysts expect that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Key Client Fiduciary Advisors LLC raised its stake in shares of Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after buying an additional 43,900 shares during the last quarter. Millennium Management LLC acquired a new position in Cytosorbents in the fourth quarter valued at approximately $30,000. Northern Trust Corp grew its stake in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the period. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after purchasing an additional 118,387 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Cytosorbents in the 4th quarter valued at $99,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.